Cigna (NYSE:CI) has earned an average rating of “Buy” from the twenty-one ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, fifteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $209.22.
Several research analysts have recently weighed in on CI shares. Zacks Investment Research upgraded Cigna from a “hold” rating to a “buy” rating and set a $231.00 target price on the stock in a report on Friday, December 22nd. ValuEngine raised shares of Cigna from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. Goldman Sachs assumed coverage on shares of Cigna in a research report on Wednesday, January 3rd. They set a “neutral” rating and a $247.00 price target on the stock. Morgan Stanley lifted their price target on shares of Cigna to $255.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. Finally, Oppenheimer lifted their price target on shares of Cigna to $237.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd.
In other Cigna news, insider Christopher J. Hocevar sold 2,759 shares of the business’s stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $191.84, for a total value of $529,286.56. Following the sale, the insider now owns 12,784 shares of the company’s stock, valued at $2,452,482.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director William D. Zollars sold 212 shares of the business’s stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $205.68, for a total value of $43,604.16. Following the completion of the sale, the director now directly owns 13,500 shares in the company, valued at approximately $2,776,680. The disclosure for this sale can be found here. In the last three months, insiders sold 86,103 shares of company stock worth $17,217,951. 1.10% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of Cigna by 1.2% during the fourth quarter. BlackRock Inc. now owns 17,155,180 shares of the health services provider’s stock worth $3,484,045,000 after acquiring an additional 206,718 shares during the period. Sanders Capital LLC increased its position in shares of Cigna by 1.8% during the fourth quarter. Sanders Capital LLC now owns 3,015,393 shares of the health services provider’s stock worth $667,646,000 after acquiring an additional 52,400 shares during the period. Geode Capital Management LLC increased its position in shares of Cigna by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 2,419,889 shares of the health services provider’s stock worth $490,343,000 after acquiring an additional 40,144 shares during the period. Swedbank increased its position in shares of Cigna by 9.0% during the fourth quarter. Swedbank now owns 1,936,346 shares of the health services provider’s stock worth $393,253,000 after acquiring an additional 159,769 shares during the period. Finally, Wells Fargo & Company MN increased its position in shares of Cigna by 16.4% during the fourth quarter. Wells Fargo & Company MN now owns 1,842,467 shares of the health services provider’s stock worth $374,187,000 after acquiring an additional 259,862 shares during the period. 88.84% of the stock is currently owned by institutional investors and hedge funds.
Shares of Cigna stock opened at $167.82 on Wednesday. The company has a market cap of $41,053.23, a PE ratio of 16.04, a P/E/G ratio of 1.02 and a beta of 0.60. Cigna has a 1-year low of $149.10 and a 1-year high of $227.13. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.37 and a current ratio of 0.37.
Cigna (NYSE:CI) last issued its earnings results on Thursday, February 1st. The health services provider reported $1.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.07. The business had revenue of $10.53 billion for the quarter, compared to analysts’ expectations of $10.28 billion. Cigna had a return on equity of 18.84% and a net margin of 5.38%. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.87 EPS. analysts expect that Cigna will post 12.9 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 10th. Shareholders of record on Monday, March 12th will be given a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.10%. The ex-dividend date of this dividend is Friday, March 9th. Cigna’s payout ratio is 0.38%.
TRADEMARK VIOLATION WARNING: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/brokerages-set-cigna-ci-target-price-at-209-22.html.
Cigna Company Profile
Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers.
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.